论文部分内容阅读
目的探讨依达拉奉联合丹红注射液治疗急性脑梗死(ACI)的临床疗效。方法选取2015年溧阳市人民医院收治的556例ACI患者,按照治疗用药不同分为对照组245例与研究组311例,对照组患者给予丹红注射液治疗,研究组在对照组基础上给予依达拉奉治疗,比较两组患者临床疗效、治疗前后神经功能缺损评分及不良反应发生情况。结果研究组患者总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者神经功能缺损评分比较,差异无统计学意义(P>0.05);治疗后研究组患者神经功能缺损评分低于对照组,差异有统计学意义(P<0.05)。两组患者均无严重不良反应发生。结论依达拉奉联合丹红注射液治疗ACI的临床疗效确切,可有效改善患者神经功能缺损,且不良反应少。
Objective To investigate the clinical efficacy of edaravone combined with Danhong injection in the treatment of acute cerebral infarction (ACI). Methods A total of 556 ACI patients admitted to Liyang People’s Hospital in 2015 were divided into control group (245 cases) and study group (311 cases), and control group received Danhong injection. The study group was given on the basis of control group Dalarpaz treatment, the clinical efficacy of two groups were compared, before and after treatment of neurological deficit score and adverse reactions. Results The total effective rate of study group was higher than that of control group, the difference was statistically significant (P <0.05). There was no significant difference in neurological deficit score between the two groups before treatment (P> 0.05). After treatment, the score of neurological deficit in study group was lower than that in control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion The clinical efficacy of edaravone combined with Danhong injection in treating ACI is good, which can effectively improve the neurological deficit with less adverse reactions.